Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • Contact

Pandemic a force of ‘positive disruption’ for telemedicine

By sarah | News | 0 comment | 16 August, 2020 | 0

By Scott Meacham

For this third column in my series exploring the long-term impact of the COVID pandemic on the fields of clinical research, I drew on the experience and insight Dr. Stephen M. Prescott, president of Oklahoma Medical Research Foundation (OMRF). The pandemic has already been a disruptor with a number of changes that seem likely to become permanent.

“Many things have changed during the time of the pandemic,” said Dr. Prescott.” We have to accept that and find ways to make those changes fit into our business.”

For OMRF and many other research institutions, those adjustments—most of them welcome—include remote work, rigorous anti-contagion practices and rules in laboratories, expansion of telemedicine, and a relaxation of FDA approval standards.

“Think about a research institution like ours,” Dr. Prescott said. “We have conferences all the time, and lab group meetings, smaller departmental meetings, and institute-wide meetings. Scientists travel here from all over the world; that’s just the way we did things. We grew up with it that way, and never took a hard look. This forced us to do something different. We got institutional subscriptions to Zoom and conference apps. We have all been pleased and a little surprised. Anything you can do on the phone, you can do from a home office.”

However, with researchers, it is different. “Some of their work can be done remotely, manuscript writing and grant applications for example, but not that much. I don’t see that changing any time soon,” said Dr. Prescott. He expects stricter safety measures industry wide as well as increased redundancy and hypervigilance to further reduce the risk of contamination.

“If an institution had an outbreak or people get sick or had to be quarantined, it could shut down research,” he said. This will keep research institutions managing people and lab access conservatively, well into 2021 and beyond.

Dr. Prescott says that the pandemic has been a force of positive disruption with the explosion in telemedicine for patients and a “fast-path” mindset at the FDA. Now that insurance companies are paying for virtual visits, adoption of telemedicine has been dramatic industry-wide. OMRF sees a large percentage of research clinic patients online.

“People with autoimmune disorders have to be hyper-vigilant,” he said. “Making routine checks virtually has been a great thing for us and for all other practices.”

Another pandemic-positive, thanks to the drive for a COVID vaccine, is a bit of FDA relaxation in requirements for proving efficacy (the ability of a drug to produce a desired or intended result).

“There has been so much emphasis on sorting out efficacy before approval,” Dr. Prescott said, “when what consumers and patients really need is for the FDA to focus on the safety issues and let the marketplace sort out the efficacy. If a drug works, everyone will figure it out.” With the FDA taking that approach with COVID, the agency may become more comfortable with a similar model for other drug approvals over time.

As destructive and exhausting as this pandemic is in the near-term, it is encouraging to consider future positives for an institution and an industry that are a cornerstone of Oklahoma’s innovation economy.

Scott Meacham is president and CEO of i2E Inc., a nonprofit corporation that mentors many of the state’s technology-based startup companies. i2E receives state appropriations from the Oklahoma Center for the Advancement of Science and Technology. Contact Meacham at i2E_Comments@i2E.org.

OMRF, pandemic, Scott Meacham, Stephen Prescott, telemedicine

Leave a Comment

Cancel reply

You must be logged in to post a comment.

i2E-300dpi-Trans-Light
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
PHONE 405/235-2305
Click HERE for printable map with directions.

Tulsa Office

618 E. Third Street, Suite 1
Tulsa, OK 74120
PHONE 918/582-5592
Click HERE for printable map with directions.
Copyright 2021 i2E, Inc. | All Rights Reserved
  • #withOklahomaStartups
  • #withOklahomaStartups
  • #withOklahomaStartups- copy
  • 2016 BrewFest
  • 2018 Paulsen Award Application
  • 2019 Business Plan Submittal Form
  • 2019 Intent to Compete
  • 2019 Oral Competition Submittal Form
  • 2019 Paulsen Award Application
  • 2020 Business Plan Submittal Form
  • 2020 Oral Competition Submittal Form
  • 2020 Paulsen Award Application
  • 2021 Official Application Form
  • 2021 Oral Competition Submittal Form
  • 2021 Paulsen Award Application
  • 4DSales
  • About
  • About i2E
  • About Us
  • ACT Tulsa
  • Add Listing
  • Alkami
  • Biolytx
  • BP Endo
  • Clear River Enviro
  • Concept Fund
  • Contact
  • COVID-19 News from i2E
  • COVID19 Resources for Scalable Startups
  • CreditPoint
  • Datebox
  • DermaMedics
  • DEX Pump
  • DigitalSix
  • Directory
  • Directory Dashboard
  • Docvia
  • Driven Analytics
  • e3
  • e3 Goes Virtual
  • e3: #withOklahomaStartups
  • Entrepreneurial Development
  • Entrepreneurial Summit
  • Entrepreneurial Summit Speakers
  • Entrepreneurs-in-Residence
  • Entrepreneurship
  • Events
  • Events
  • Exaptive
  • Exerbotics
  • Expert TA
  • Founder’s Book Nook
  • Home
  • Home
  • i2E Directory
  • i2E Events
  • iMCI
  • iMCI Investment Funds
  • Investments
  • iRecommend
  • Kirrhos
  • Letter from iMCI’s Executive in Residence in a time of great uncertainty
  • Library
  • Lifetone
  • Linear Health Sciences
  • Love’s Cup
    • Forms
    • High Growth
    • Paulsen Awards
    • Small Business
    • Timeline
  • Love’s Cup is Unstoppable
  • Love’s Cup W-9
  • MaxQ
  • Moleculera Labs
  • Monscierge
  • MS Pen Technologies
  • My Account
  • News
  • Newsletter
  • Newsletter Archive
  • OKBio
  • OKBio Directory
  • OMRF Glioblastoma
  • Otologics Pharmaceuticals
  • Past Winners
  • PhotoniCare
  • PolySkope Labs
  • Portfolio
  • Portfolio 3
  • Private Partners Opportunity Fund
  • Progentec Diagnostics
  • Q&A with Kevin Moore
  • Q&A with Michael Basch
  • Quarterly Report
  • Raw Space for Rent
  • Resources
  • Roll to Roll Technologies
  • Selexys Pharmaceuticals
  • Send a Ride
  • Simergent
  • Spiers New Technologies
  • Synercon Technologies
  • Tailwind
  • Ten Nine Technologies
  • Testimonials
  • Tetherex Pharmaceuticals
  • The Greg Main Distinguished Scholar Award
  • THG Energy Solutions
  • Thoughts from local business leaders and startup founders on the effects of COVID on their industry
  • Thoughts Post Shut In
  • Tulsa Collab: COVID-19 Efforts & Resources for Entrepreneurs
  • Tulsa GEW
  • Valve Systems International
  • Venture Advisory Services
  • Video
  • Virtuoso
  • Webmail Test Page
  • WeGoLook
  • Well Checked Systems
  • Whiteboard CRM
i2E